Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGTX Cognition Therapeutics	$2.43 -2.0%	$1.06	$0.22 ▼ $3.83	$178.66M	1.29	11.89 million shs	5.33 million shs
MNPR Monopar Therapeutics	$34.15 -5.3%	$37.94	$2.25 ▼ $54.30	$210.70M	1.2	33,801 shs	15,130 shs
SLS SELLAS Life Sciences Group	$1.92	$1.83	$0.77 ▼ $2.27	$202.17M	2.54	1.83 million shs	1.24 million shs
VRCA Verrica Pharmaceuticals	$5.59 +0.7%	$6.58	$3.82 ▼ $25.20	$52.85M	1.78	45,468 shs	41,112 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGTX Cognition Therapeutics	0.00%	-23.58%	+264.10%	+684.12%	+241.58%
MNPR Monopar Therapeutics	0.00%	+12.26%	-16.07%	+6.35%	+1,328.87%
SLS SELLAS Life Sciences Group	0.00%	+0.52%	+15.66%	+17.07%	+48.84%
VRCA Verrica Pharmaceuticals	0.00%	-6.68%	-0.89%	+5.25%	-76.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGTX Cognition Therapeutics	2.3704 of 5 stars	2.6	4.0	0.0	3.1	1.7	0.6
MNPR Monopar Therapeutics	2.6418 of 5 stars	3.4	4.0	0.0	2.2	2.5	0.0
SLS SELLAS Life Sciences Group	2.8913 of 5 stars	3.5	2.0	0.0	4.4	1.7	0.6
VRCA Verrica Pharmaceuticals	4.529 of 5 stars	3.1	5.0	4.7	3.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGTX Cognition Therapeutics	3.25	Buy	$2.83	16.60% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$66.00	93.27% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	264.58% Upside
VRCA Verrica Pharmaceuticals	2.20	Hold	$80.00	1,331.13% Upside

Current Analyst Ratings Breakdown

Latest VRCA, CGTX, SLS, and MNPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$74.00
8/26/2025	MNPR Monopar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
8/13/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
8/8/2025	CGTX Cognition Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/26/2025	CGTX Cognition Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	$0.31 per share	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
SLS SELLAS Life Sciences Group	$1M	202.18	N/A	N/A	$0.13 per share	14.77
VRCA Verrica Pharmaceuticals	$7.57M	6.98	N/A	N/A	($1.07) per share	-5.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGTX Cognition Therapeutics	-$33.97M	-$0.67	N/A	N/A	N/A	N/A	-251.23%	-130.75%	11/12/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.33	N/A	N/A	N/A	N/A	-41.76%	-39.49%	11/14/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	N/A	N/A	N/A	N/A	-132.51%	-92.79%	11/12/2025 (Estimated)
VRCA Verrica Pharmaceuticals	-$76.58M	-$8.28	N/A	N/A	N/A	N/A	N/A	-115.48%	11/3/2025 (Estimated)

Latest VRCA, CGTX, SLS, and MNPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MNPR Monopar Therapeutics	-$0.47	-$0.35	+$0.12	-$0.35	N/A	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A
8/12/2025	Q2 2025	VRCA Verrica Pharmaceuticals	-$0.70	$0.02	+$0.72	$0.02	$4.37 million	$12.70 million
8/7/2025	Q2 2025	CGTX Cognition Therapeutics	-$0.12	-$0.11	+$0.01	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGTX Cognition Therapeutics	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGTX Cognition Therapeutics	N/A	1.54	1.54
MNPR Monopar Therapeutics	N/A	33.93	33.93
SLS SELLAS Life Sciences Group	N/A	4.91	4.91
VRCA Verrica Pharmaceuticals	N/A	1.26	1.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGTX Cognition Therapeutics	43.35%
MNPR Monopar Therapeutics	1.83%
SLS SELLAS Life Sciences Group	17.38%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
CGTX Cognition Therapeutics	14.40%
MNPR Monopar Therapeutics	20.50%
SLS SELLAS Life Sciences Group	1.20%
VRCA Verrica Pharmaceuticals	54.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGTX Cognition Therapeutics	20	73.52 million	62.94 million	Not Optionable
MNPR Monopar Therapeutics	10	6.17 million	4.91 million	Not Optionable
SLS SELLAS Life Sciences Group	10	105.30 million	104.03 million	Not Optionable
VRCA Verrica Pharmaceuticals	40	9.45 million	4.35 million	Optionable

VRCA, CGTX, SLS, and MNPR Headlines

Recent News About These Companies

101,125 Shares in Verrica Pharmaceuticals Inc. $VRCA Acquired by Kovitz Investment Group Partners LLC

August 26, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Declines By 32.3%

August 22, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Drops By 32.3%

August 22, 2025 | americanbankingnews.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results, Beats Expectations By $0.12 EPS

August 14, 2025 | marketbeat.com

Verrica Posts Profit in Fiscal Q2

August 14, 2025 | theglobeandmail.com

Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 13, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 13, 2025 | finanznachrichten.de

Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Verrica Pharmaceuticals Regains Nasdaq Compliance

August 12, 2025 | msn.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates

August 12, 2025 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

August 12, 2025 | globenewswire.com

3VRCA : What to Expect from Verrica Pharmaceuticals's Earnings

August 11, 2025 | benzinga.com

Verrica Pharmaceuticals (VRCA) Expected to Announce Quarterly Earnings on Wednesday

August 7, 2025 | marketbeat.com

Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025

August 6, 2025 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Average Recommendation of "Hold" from Brokerages

August 5, 2025 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0.2% - Should You Buy?

August 3, 2025 | marketbeat.com

Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Rises By 1,164.0%

August 2, 2025 | marketbeat.com

Verrica Pharmaceuticals Implements Reverse Stock Split

August 1, 2025 | theglobeandmail.com

Verrica Pharmaceuticals Inc. (VRCA) Latest Stock News & Headlines ...

July 12, 2025 | finance.yahoo.com

Verrica Pharmaceuticals Inc News (VRCA) - Investing.com

July 11, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRCA, CGTX, SLS, and MNPR Company Descriptions

Cognition Therapeutics NASDAQ:CGTX

$2.43 -0.05 (-2.02%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.48 +0.05 (+2.10%)

As of 04:03 AM Eastern

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Monopar Therapeutics NASDAQ:MNPR

$34.15 -1.91 (-5.30%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$33.44 -0.70 (-2.06%)

As of 08/29/2025 06:38 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

SELLAS Life Sciences Group NASDAQ:SLS

$1.92 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.89 -0.03 (-1.35%)

As of 04:03 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Verrica Pharmaceuticals NASDAQ:VRCA

$5.59 +0.04 (+0.72%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$6.00 +0.41 (+7.33%)

As of 04:00 AM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time